Role of Insulin Resistance in MAFLD
Open accessThe DOI matches its Crossref record; 195 of the 195 references it cites were found in a registry or an index.
Abstract
Many studies have reported that metabolic dysfunction is closely involved in the complex mechanism underlying the development of non-alcoholic fatty liver disease (NAFLD), which has prompted a movement to consider renaming NAFLD as metabolic dysfunction-associated fatty liver disease (MAFLD). Metabolic dysfunction in this context encompasses obesity, type 2 diabetes mellitus, hypertension, dyslipidemia, and metabolic syndrome, with insulin resistance as the common underlying pathophysiology. Imbalance between energy intake and expenditure results in insulin resistance in various tissues and alteration of the gut microbiota, resulting in fat accumulation in the liver. The role of genetics has also been revealed in hepatic fat accumulation and fibrosis. In the process of fat accumulation in the liver, intracellular damage as well as hepatic insulin resistance further potentiates inflammation, fibrosis, and carcinogenesis. Increased lipogenic substrate supply from other tissues, hepatic zonation of Irs1, and other factors, including ER stress, play crucial roles in increased hepatic de novo lipogenesis in MAFLD with hepatic insulin resistance. Herein, we provide an overview of the factors contributing to and the role of systemic and local insulin resistance in the development and progression of MAFLD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Given that insulin resistance (IR) is widely recognized as the key underlying mechanism of metabolic syndrome, it is reasonable to consider IR as a central factor in the pathogenesis of MASLD, which can be viewed as the hepatic manifestation of metabolic syndrome [2,9-12].”
The cited source says what the claim attributes to it.
In the citing paper
“ChREBP, which is activated by carbohydrate uptake [9,34,78,83].”
The cited source says what the claim attributes to it.
In the citing paper
“Among the core insulin signaling mediators—including INSR, IRS1, IRS2, AKT1, and AKT2—IRS1 shows marked zonal expression, with approximately 2-fold higher levels in PV compared to PP regions [9,20].”
In the citing paper
“Many studies have shown that insulin- resistant conditions are accompanied by a substantial increase in MTP and apolipoprotein C3 (ApoCIII) expression and the production of hepatic VLDL-ApoB and VLDL-TG [2, 9,108,111].”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
MORA, A., LIPINA, C., TRONCHE, F., SUTHERLAND, C., & ALESSI, D. R. (2005) · Biochemical Journal · doi:10.1042/bj20041782 · Cited by 92
RetractedSarcopenia: revised European consensus on definition and diagnosis
Cruz-Jentoft, A. J., Bahat, G., Bauer, J., Boirie, Y., Bruyère, O., Cederholm, T., Cooper, C., Landi, F., Rolland, Y., Sayer, A. A., et al. (2019) · Age and Ageing · doi:10.1093/ageing/afy169 · Cited by 13,818
Younossi, Z. M., Koenig, A. B., Abdelatif, D., Fazel, Y., Henry, L., & Wymer, M. (2016) · Hepatology · doi:10.1002/hep.28431 · Cited by 10,781
Adipose Expression of Tumor Necrosis Factor-α: Direct Role in Obesity-Linked Insulin Resistance
Hotamisligil, G. S., Shargill, N. S., & Spiegelman, B. M. (1993) · Science · doi:10.1126/science.7678183 · Cited by 7,518
Chalasani, N., Younossi, Z., Lavine, J. E., Charlton, M., Cusi, K., Rinella, M., Harrison, S. A., Brunt, E. M., & Sanyal, A. J. (2018) · Hepatology · doi:10.1002/hep.29367 · Cited by 7,239 · cited 2×
“, hepatocyte ballooning), with or without fibrosis [2].”
BackgroundMetabolic Endotoxemia Initiates Obesity and Insulin Resistance
Cani, P. D., Amar, J., Iglesias, M. A., Poggi, M., Knauf, C., Bastelica, D., Neyrinck, A. M., Fava, F., Tuohy, K. M., Chabo, C., et al. (2007) · Diabetes · doi:10.2337/db06-1491 · Cited by 6,638
Matsuda, M., & DeFronzo, R. A. (1999) · Diabetes Care · doi:10.2337/diacare.22.9.1462 · Cited by 5,621
Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention
Younossi, Z., Anstee, Q. M., Marietti, M., Hardy, T., Henry, L., Eslam, M., George, J., & Bugianesi, E. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2017.109 · Cited by 5,249 · cited 1×
“The global prevalence of NAFLD is estimated at 24%; the highest rates are reported from South America and the Middle East, followed by Asia, the USA, and Europe [3].”
BackgroundSREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver
Horton, J. D., Goldstein, J. L., & Brown, M. S. (2002) · Journal of Clinical Investigation · doi:10.1172/jci15593 · Cited by 4,794
Eslam, M., Newsome, P. N., Sarin, S. K., Anstee, Q. M., Targher, G., Romero-Gomez, M., Zelber-Sagi, S., Wai-Sun Wong, V., Dufour, J.-F., Schattenberg, J. M., et al. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.03.039 · Cited by 4,472
Cited by
Items 101–200 of 506
Polyphenols alleviate metabolic disorders: the role of ubiquitin-proteasome system
Gu, W., Wu, G., Chen, G., Meng, X., Xie, Z., & Cai, S. (2024) · Frontiers in Nutrition · doi:10.3389/fnut.2024.1445080 · Cited by 22
Caffeine ameliorates metabolic-associated steatohepatitis by rescuing hepatic Dusp9
Xin, X., Chen, C., Xu, X., Lv, S., Sun, Q., An, Z., Chen, Y., Xiong, Z., Hu, Y., & Feng, Q. (2025) · Redox Biology · doi:10.1016/j.redox.2025.103499 · Cited by 21
Metabolic dysfunction associated fatty liver disease in healthy weight individuals
Méndez‐Sánchez, N., Brouwer, W. P., Lammert, F., & Yilmaz, Y. N. (2024) · Hepatology International · doi:10.1007/s12072-024-10662-w · Cited by 21
EL-Shial, E. M., Kabbash, A. M., El‐Aasr, M., El-Feky, O. A., & El-Sherbeni, S. A. (2023) · Molecules · doi:10.3390/molecules28020879 · Cited by 21
Dong, Y., Hu, M., Tan, K., & Dai, R. (2023) · Epigenetics · doi:10.1080/15592294.2023.2239592 · Cited by 20
Ma, X., Jia, J., Cui, H., Zhou, J., Tian, F., Yang, J., Zhang, Y., Dai, J., & Cao, L. (2024) · BMC Gastroenterology · doi:10.1186/s12876-024-03471-w · Cited by 20
Chen, Q., Gao, Y., Yang, F., Deng, H., Wang, Y., & Li, Y. (2022) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2022.102603 · Cited by 20
Physiological and pathophysiological actions of insulin in the liver
Kubota, N., Kubota, T., & Kadowaki, T. (2025) · Endocrine Journal · doi:10.1507/endocrj.ej24-0192 · Cited by 19
Self-citationMetabolic (dysfunction)-associated fatty liver disease metrics and contributions to liver research
Suoh, M., Esmaili, S., Eslam, M., & George, J. (2024) · Hepatology International · doi:10.1007/s12072-024-10731-0 · Cited by 19
Barbhuiya, P. A., Ahmed, A., Dutta, P. P., Sen, S., & Pathak, M. P. (2025) · Current Nutrition Reports · doi:10.1007/s13668-024-00598-w · Cited by 19
Yadav, P., Quadri, K., Kadian, R., Waziri, A., Agrawal, P., & Alam, M. S. (2024) · iLiver · doi:10.1016/j.iliver.2024.100131 · Cited by 19
The Role of Endoplasmic Reticulum Stress in Metabolic Diseases
Sak, F., Şengül, F., & Vatansev, H. (2024) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2024.0013 · Cited by 19
Jia, J., Liu, R., Wei, W., Yu, F., Yu, X., Shen, Y., Chen, C., Cai, Z., Wang, C., Zhao, Z., et al. (2021) · Frontiers in Physiology · doi:10.3389/fphys.2021.762242 · Cited by 18
Losasso, M. R., Parussolo, M. L. C., Silva, A. O., Direito, R., Quesada, K. R., Detregiachi, C. R. P., Bechara, M. D., Méndez‐Sánchez, N., Abenavoli, L., Araújo, A. C., et al. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26104673 · Cited by 18
Cao, Y., Fang, X., Sun, M., Zhang, Y., Shan, M., Lan, X., Zhu, D., & Luo, H. (2023) · Phytotherapy Research · doi:10.1002/ptr.7932 · Cited by 18
Study on inflammation and fibrogenesis in MAFLD from 2000 to 2022: a bibliometric analysis
Luo, K., Chen, Y., Fang, S., Wang, S., Wu, Z., & Li, H. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1231520 · Cited by 18
Li, F., Yuan, R., Zhang, J., Su, B., & Qi, X. (2025) · Asian Journal of Pharmaceutical Sciences · doi:10.1016/j.ajps.2025.101025 · Cited by 18
Kathirvel, E., Morgan, K., Malysheva, O., Caudill, M. A., & Morgan, T. R. M. (2024) · Frontiers in Nutrition · doi:10.3389/fnut.2024.1409972 · Cited by 18
PM2.5 induced liver lipid metabolic disorders in C57BL/6J mice
Zhang, C., Ma, T., Liu, C., Ma, D., Wang, J., Liu, M., Ran, J., Wang, X., & Deng, X. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1212291 · Cited by 18
Grilo, L. F., Diniz, M. S., Tocantins, C., Areia, A. L., & Pereira, S. P. (2022) · Obesities · doi:10.3390/obesities2030019 · Cited by 17
Li, Z., Ouyang, H., & Zhu, J. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1195146 · Cited by 17
Crosstalk in extrahepatic and hepatic system in NAFLD / NASH
Duan, Y., Yang, Y. Z., Zhao, S., Bai, Y., Yao, W., Gao, X., & Yin, J. (2024) · Liver International · doi:10.1111/liv.15967 · Cited by 17
Rabadán-Chávez, G. M., de la Garza, R. I. D., & Jacobo‐Velázquez, D. A. (2023) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2023.166853 · Cited by 17
Lv, Z., Ren, Y., Li, Y., Niu, F., Li, Z., Li, M., Li, X., Li, Q., Huang, D.-Q., Yu, Y., et al. (2024) · Molecular Medicine · doi:10.1186/s10020-024-00889-6 · Cited by 17
Endoplasmic reticulum stress in liver fibrosis: Mechanisms and therapeutic potential
Wang, T., Xia, G., Li, X., Gong, M., & Lv, X. (2025) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2025.167695 · Cited by 16
Elhoseeny, M. M., Rageh, F., Rezk, S. M., & Othman, A. A. A. (2025) · Scientific Reports · doi:10.1038/s41598-025-95753-w · Cited by 16
Dai, X., Zhou, G., & Xu, L. (2022) · PLoS ONE · doi:10.1371/journal.pone.0279274 · Cited by 16
Naz, M. S. G., Mousavi, M. A., Firouzi, F., Momenan, A. A., Azizi, F., & Tehrani, F. R. (2024) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.490 · Cited by 16
Zhang, F., Liu, L., & Li, W. (2025) · Nutrition Journal · doi:10.1186/s12937-025-01081-0 · Cited by 16
Yan, J. Y., Zhou, J. F., Ding, Y., & Tu, C. (2024) · Frontiers in Nutrition · doi:10.3389/fnut.2024.1340453 · Cited by 16
Katsuyama, H., Hakoshima, M., Kaji, E., Mino, M., Kakazu, E., Iida, S., Adachi, H., Kanto, T., & Yanai, H. (2024) · Biomedicines · doi:10.3390/biomedicines12051001 · Cited by 15
Trochimczyk, K., Flisiak‐Jackiewicz, M., Bobrus‐Chociej, A., Lebensztejn, A., Wojtkowska, M., Jamiołkowski, J., & Lebensztejn, D. M. (2024) · Medical Science Monitor · doi:10.12659/msm.943375 · Cited by 15
LncRNA Snhg3 aggravates hepatic steatosis via PPARγ signaling
Xie, X., Gao, M., Zhao, W. G., Li, C., Zhang, W., Yang, J., Zhang, Y., Chen, E., Guo, Y., Guo, Z., et al. (2024) · eLife · doi:10.7554/elife.96988.4 · Cited by 15
Wu, T., Ye, J., Mo, S., Ye, M., Li, X., Li, Q., Wang, W., Zheng, Q., Luo, K., Zhang, Y., et al. (2024) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.16554 · Cited by 15
Exosome prospects in the diagnosis and treatment of non-alcoholic fatty liver disease
Tamimi, A., Javid, M., Sedighi-Pirsaraei, N., & Mirdamadi, A. (2024) · Frontiers in Medicine · doi:10.3389/fmed.2024.1420281 · Cited by 15
Lipid metabolism-MAFLD crosstalk: mechanisms and therapy
Li, B., Piao, S., Fu, Y., Fu, Q., Qin, P., Kong, W. K., Ma, Y., Zhang, Z., Fang, X., & Hu, X. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1785178 · Cited by 15
The transition from NAFLD to MASLD: implications for Diagnosis, Prognosis, and Clinical Management
Acierno, C., Nevola, R., Barletta, F., Zielińska, K., Rinaldi, L., Sasso, F. C., Conte, C., Adinolfi, L. E., & Caturano, A. (2025) · Exploration of Medicine · doi:10.37349/emed.2025.1001365 · Cited by 14
Wayal, V., & Hsieh, C. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115724 · Cited by 14
Chen, J., Liu, Z., Lyu, J., & Jiang, G. (2024) · Hepatobiliary & pancreatic diseases international · doi:10.1016/j.hbpd.2024.08.001 · Cited by 14
El‐Sehrawy, A. A. M. A., Rashid, T. A., Ullah, M. I., Uthirapathy, S., Ganesan, S., Singh, A., Devi, A., Joshi, K. K., Jasim, A. S., & KADHIM, A. J. (2025) · Functional & Integrative Genomics · doi:10.1007/s10142-025-01579-0 · Cited by 14
Zani, S. C. D. C., Wang, R., Veida-Silva, H., Clugston, R. D., Yue, J. T. Y., Mori, M. A. S., Wu, J., & Chan, C. B. (2023) · Metabolites · doi:10.3390/metabo13020174 · Cited by 14
Abbate, M., Parvanova, A. I., López‐González, Á. A., Yáñez, A. M., Bennasar‐Veny, M., Ramírez‐Manent, J. I., Reseghetti, E., & Ruggenenti, P. (2024) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3810 · Cited by 14
Alam, N., Jia, L., Cheng, A., Ren, H., Fu, Y., Ding, X., Haq, I. U., & Liu, E. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1390483 · Cited by 14
Yang, H., Ran, S., Zhou, Y., Shi, Q., Yu, J., Wang, W., Sun, C., Li, D., Hu, Y., Pan, C., et al. (2024) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.4c05671 · Cited by 14
Xie, J., Zhong, F., Guo, Z., Li, X., Wang, J., Gao, Z., Chang, B., & Yang, J. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.960835 · Cited by 14
Gao, J., Cang, X., Liu, L., Lin, J., Zhu, S., Liu, L., Liu, X., Zhu, J., & Xu, C. (2024) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.70096 · Cited by 14
Zwierz, M., Chabowski, A., & Sztolsztener, K. (2023) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2023.109811 · Cited by 14
A Machine Learning-Based Method for Detecting Liver Fibrosis
Suárez, M., Martínez, R., Torres, A., Ramón, A., Blasco, P., & Mateo, J. (2023) · Diagnostics · doi:10.3390/diagnostics13182952 · Cited by 14
Xing, Y., Chen, J., Liu, J., Song, G., & Ma, H. (2022) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s350468 · Cited by 14
Woerkom, A. V., Harney, D., Nagarajan, S. R., Hakeem-Sanni, M. F., Lin, J., Hooke, M., Pulpitel, T., Cooney, G. J., Larance, M., Saunders, D. N., et al. (2024) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00013.2024 · Cited by 13
Prevalence and Risk Factors of Metabolic-Associated Fatty Liver Disease Among Hospital Staff
Zhang, D., Zhang, L., Chen, S., Chen, R., Zhang, X., & Bai, F. (2023) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s407657 · Cited by 13
Psychology and Pathophysiological Outcomes of Eating
Takada, A., & Himmerich, H. (2021) · IntechOpen eBooks · doi:10.5772/intechopen.92917 · Cited by 12
RNA-binding proteins in metabolic-associated fatty liver disease (MAFLD): From mechanism to therapy
Xu, J., Liu, X., Shu-qin, W., Zhang, D., Liu, X., Xia, P., Ling, J., Zheng, K., Xu, M., Shen, Y., et al. (2023) · BioScience Trends · doi:10.5582/bst.2022.01473 · Cited by 12
Ha, J., Hong, O., Han, K., & Kwon, H.-S. (2024) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2024.111584 · Cited by 12
Guo, X., Zhou, Q., Jin, J., Lan, F., Wen, C., Li, J., Yang, N., & Sun, C. (2023) · Journal of Animal Science and Biotechnology/Journal of animal science and biotechnology · doi:10.1186/s40104-023-00910-8 · Cited by 12
Taurine alleviated hepatic steatosis in oleic acid-treated-HepG2 cells and rats fed a high-fat diet
Song, Q., Guo, J., Xun, Y. F., Ou, T., Zhang, J., Li, H. Z., Mi, S., Zhang, Y. Z., Oda, H., & Chen, W. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e16401 · Cited by 12
Wen, W., Fan, H., Zhang, S., Hu, S., Chen, C., Tang, J., You, Y., Wang, C., Li, J., Luo, L., et al. (2024) · The American Journal of the Medical Sciences · doi:10.1016/j.amjms.2024.06.022 · Cited by 12
Kishi, H., Usui, I., Jojima, T., Fujisaka, S., Wakamatsu, S., Mizunuma-Inoue, Y., Niitani, T., Sakurai, S., Iijima, T., Tomaru, T., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232315309 · Cited by 12
Amer, A. E., Ghoneim, H. A., Abdelaziz, R. R., Shehatou, G. S. G., & Suddek, G. M. (2024) · BMC Pharmacology and Toxicology · doi:10.1186/s40360-024-00820-z · Cited by 12
Ryu, G., Ko, M., Lee, S.-Y., Park, S. I., Choi, J. W., Lee, J. Y., Kim, J. Y., & Kwon, H. J. (2024) · Biomolecules · doi:10.3390/biom14121505 · Cited by 12
Gao, Y., Wang, P., Lu, S., & Ma, W. (2023) · PubMed Central · doi:10.12122/j.issn.1673-4254.2023.10.06 · Cited by 12
Ebrahimi, F., Simon, T. G., Hagström, H., Sun, J., Bergman, D., Forss, A., Roelstraete, B., Engstrand, L. G., & Ludvigsson, J. F. (2023) · Liver International · doi:10.1111/liv.15663 · Cited by 12
Dovale-Rosabal, G., Espinosa, A., Rodríguez, A., Barriga, A., Palomino-Calderón, A., Romero, N., Troncoso, R., & Aubourg, S. P. (2022) · Molecules · doi:10.3390/molecules27227702 · Cited by 12
Silymarin for adults with metabolic dysfunction-associated steatotic liver disease
Wang, C., Shang, Y., Kanaan, G., Chai, L., Li, H., & Qi, X. (2025) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd015524.pub2 · Cited by 11
Hu, W., Lyu, X., Xu, H., Guo, X., Zhu, H., Pan, H., Wang, L., Yang, H., & Gong, F. (2023) · Nutrients · doi:10.3390/nu15132954 · Cited by 11
Dang, H. N. N., Luong, T. V., Tran, T. T., & Anh, T. H. (2024) · Health Science Reports · doi:10.1002/hsr2.2102 · Cited by 11
Yanagisawa, H., Maeda, H., Noguchi, I., Tanaka, M., Wada, N., Nagasaki, T., Kobayashi, K., Kanazawa, G., Taguchi, K., Chuang, V. T. G., et al. (2024) · Redox Biology · doi:10.1016/j.redox.2024.103314 · Cited by 10
“Recent reports have shown that metabolic dysfunction-associated steatotic liver disease (MASLD) and MASH can be associated with metabolic syndrome, and that affected patients often have impaired glucose tolerance [73 – 75].”
BackgroundShen, S., & Pan, L. (2024) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2024.12387 · Cited by 10
Sarcopenia in the setting of nonalcoholic fatty liver
Arrese, M. A., Cabello‐Verrugio, C., Arab, J. P., Francisco Barrera, M., Baudrand, R., Guarda, F. J., Gul, I., & Cabrera, D. (2022) · Metabolism and Target Organ Damage · doi:10.20517/mtod.2021.16 · Cited by 10
Masson, W. M., Barbagelata, L., Leiva, E. G., Genua, I., & Nogueira, J. P. (2023) · Indian Journal of Gastroenterology · doi:10.1007/s12664-023-01457-2 · Cited by 10
Lei, K., Chen, Y., Wu, J., Lin, Y., Bai, Y., Cao, H., Che, Q., Guo, J., & Su, Z. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.142275 · Cited by 10
Application of PPAR Ligands and Nanoparticle Technology in Metabolic Steatohepatitis Treatment
Vu, H. T., Nguyen, V. D., Ikenaga, H., & Matsubara, T. (2024) · Biomedicines · doi:10.3390/biomedicines12081876 · Cited by 10
Fu, Y., Li, G., Feng, Z., Liu, J., Wang, X., Wang, T., & Liu, J. (2024) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s449300 · Cited by 10
Dong, J., Liu, C., Lu, J., Wang, L., Xie, S., Ji, L., & Lu, B. (2023) · European Journal of Clinical Investigation · doi:10.1111/eci.14082 · Cited by 10
Siqueira, J. S., Garcia, J. L., Ferron, A. J. T., Moreto, F., Sormani, L. E., Costa, M. R., Palacio, T. L. N., Nai, G. A., Aldini, G., Francisqueti‐Ferron, F. V., et al. (2024) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2024.109607 · Cited by 10
Rui, F., Yang, H., Hu, X., Xue, Q. C., Xu, Y., Shi, J., & Li, J. (2022) · Infectious Microbes & Diseases · doi:10.1097/im9.0000000000000089 · Cited by 10
He, C., Zhou, F., & Fang, X. (2026) · Medicine · doi:10.1097/md.0000000000046886 · Cited by 9
MASLD Under the Microscope: How microRNAs and Microbiota Shape Hepatic Metabolic Disease Progression
Asero, C., Franzè, M. S., Cacciola, I., & Gangemi, S. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26178633 · Cited by 9
Zhu, Y., Dong, X., Zhou, H., Li, Z., Wang, B., Song, Y., Liu, Z., Lu, X., Zhang, Y., Huang, Y., et al. (2025) · Advanced Science · doi:10.1002/advs.202412827 · Cited by 9
Gene-based therapies for steatotic liver disease
Iakovleva, V., & de Jong, Y. P. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.04.024 · Cited by 9
Ekpor, E., Akyirem, S., & Duodu, P. A. (2024) · PLOS Global Public Health · doi:10.1371/journal.pgph.0002835 · Cited by 9
Liu, S., Duan, J.-H., Chen, Y., Gu, S.-L., Yu-hua, H., Xue, M.-M., & Yue, J.-Y. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1555300 · Cited by 9
Astaxanthin-Based Biomaterials for Tissue Repair and Drug Delivery Systems
Wang, Y., Xue, H., Sun, C., Gu, Q., Chen, L., Lin, Z., Xu, L., Lei, L., Li, Q., & Zhao, Z. (2025) · Biomaterials Research · doi:10.34133/bmr.0282 · Cited by 9
Ehret, V., Ustsinau, U., Friske, J., Scherer, T., Fürnsinn, C., Helbich, T. H., Philippe, C., & Krššák, M. (2024) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.29437 · Cited by 9
Folestad, E. B., & Falkevall, A. (2024) · Current Opinion in Endocrine and Metabolic Research · doi:10.1016/j.coemr.2024.100559 · Cited by 9
Ma, J., Chen, W., Vaishnani, D., Wang, C., Xue, S., Yang, Q., Tong, Y., Lei, N., Zhao, Z., & Ying, F. (2025) · Drug Design Development and Therapy · doi:10.2147/dddt.s511372 · Cited by 9
Cao, Y., Li, H.-Z., Zhao, J., Sun, Y., Jin, X.-W., Lv, S., Luo, J.-Y., Fang, X., Wen, W., & Liao, J. (2022) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2022/2264394 · Cited by 9
Wu, Z., Huang, K., Bao, S., Zhang, X., Li, J., Kong, W., Shi, Y., & Xie, Y. (2024) · Scandinavian Journal of Gastroenterology · doi:10.1080/00365521.2024.2305268 · Cited by 9
Fang, B., Mo, R., Lin, X., Huang, Q.-F., & Huang, R. (2024) · Phytomedicine · doi:10.1016/j.phymed.2024.156016 · Cited by 9
Abosheaishaa, H. M., Nassar, M., Abdelhalim, O., Bahbah, A. A., Abbas, S., Morsi, S. M., Ghallab, M., Alagha, Z., Omran, A., Elfert, K., et al. (2024) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0000000000002721 · Cited by 9
Liu, J., Ma, C., Wang, Y., & Rao, H. (2026) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2025.00612 · Cited by 9
Huang, M., Zhang, X., Zhou, R., Song, Y., Zhang, J., & Wu, J. (2024) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2024.1491696 · Cited by 8
Barbalho, S. M., Laurindo, L. F., Valenti, V. E., Méndez‐Sánchez, N., Ramírez-Mejía, M. M., & Goulart, R. D. Á. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262311547 · Cited by 8
Zhang, C.-Y., Zhu, X., Sun, W.-D., Bi, S.-Z., Lai, S.-Y., An-Liu, & Li, J.-H. (2025) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2025.110558 · Cited by 8
Rustamov, N., Ma, Y., Park, J.-S., Wang, F., Ma, H., Sui, G.-Y., Moon, G., Yoo, H., & Roh, Y. (2024) · Foods · doi:10.3390/foods13132137 · Cited by 8
Yao, K. (2025) · BMC Public Health · doi:10.1186/s12889-025-21379-2 · Cited by 8
Hakimullah, Ullah, Z., Rehman, W. U., Rashid, M. U., Khan, S. A., Hussain, R., Khan, Y., Iqbal, T., Felemban, S., & Khowdiary, M. M. (2024) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2024.138726 · Cited by 8
Baptista, C., Esteves, F., Fallowfield, J. A., Kendall, T. J., Nelson, L. J., & Kranendonk, M. (2026) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-026-01202-y · Cited by 8
Huang, X., Li, Z., Zhai, Z., Wang, Q., Wei, R., Mo, J., Huang, J., & Lu, W. (2024) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s447897 · Cited by 8
Kołakowski, A., Dziemitko, S., Chmielecka, A., Żywno, H., Bzdęga, W., Charytoniuk, T., Chabowski, A., & Konstantynowicz-Nowicka, K. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231911380 · Cited by 8
Metadata
- Authors
- Sakurai, Y., Kubota, N., Yamauchi, T., & Kadowaki, T.
- Affiliations
- The University of Tokyo (JP)
- National Institute of Biomedical Innovation, Health and Nutrition (JP)
- Toranomon Hospital (JP)
- Corresponding author
- Kubota, Naoto
- Kadowaki, Takashi
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2021-04-16
- Volume
- 22
- Issue
- 8
- Pages
- 4156
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC8072900
- OpenAlex
- W3155254720
- Cited by
- 448
- References
- 195
- Citations by year
- 2026: 72 · 2025: 129 · 2024: 125 · 2023: 80 · 2022: 37 · 2021: 5
- FWCI
- 9.50
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Japan Society for the Promotion of Science (19K17977)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diet, Metabolism, and Disease
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Keywords
- non-alcoholic fatty liver disease, insulin resistance, hepatic insulin resistance, hepatic steatosis, liver fibrosis, de novo lipogenesis, gut microbiota, metabolic syndrome, obesity, type 2 diabetes, endoplasmic reticulum stress, liver inflammation, hepatocarcinogenesis
- MeSH terms
- Animals, Humans, Insulin, Signal Transduction, Metabolic Syndrome, Lipogenesis, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.